452 related articles for article (PubMed ID: 20172040)
1. Favorable outcome in patients with acute myelogenous leukemia with the nucleophosmin gene mutation autografted after conditioning with high-dose continuous infusion of idarubicin and busulfan.
Ferrara F; Izzo T; Criscuolo C; Riccardi C; Muccioli G; Viola A; Pane F; Palmieri S
Biol Blood Marrow Transplant; 2010 Jul; 16(7):1018-24. PubMed ID: 20172040
[TBL] [Abstract][Full Text] [Related]
2. Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 yr with acute myeloid leukaemia.
Scholl S; Theuer C; Scheble V; Kunert C; Heller A; Mügge LO; Fricke HJ; Höffken K; Wedding U
Eur J Haematol; 2008 Mar; 80(3):208-15. PubMed ID: 18081718
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors in normal karyotype acute myeloid leukemia in the absence of the FLT3-ITD mutation.
Jiang A; Jiang H; Brandwein J; Kamel-Reid S; Chang H
Leuk Res; 2011 Apr; 35(4):492-8. PubMed ID: 20684989
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.
Green CL; Koo KK; Hills RK; Burnett AK; Linch DC; Gale RE
J Clin Oncol; 2010 Jun; 28(16):2739-47. PubMed ID: 20439648
[TBL] [Abstract][Full Text] [Related]
5. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.
Shamaa S; Laimon N; Aladle DA; Azmy E; Elghannam DM; Salem DA; Taalab MM
Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998
[TBL] [Abstract][Full Text] [Related]
6. Different clinical importance of FLT3 internal tandem duplications in AML according to FAB classification: possible existence of distinct leukemogenesis involving monocyte differentiation pathway.
Koh Y; Park J; Ahn KS; Kim I; Bang SM; Lee JH; Yoon SS; Soon Lee D; Yiul Lee Y; Park S; Kim BK
Ann Hematol; 2009 Nov; 88(11):1089-97. PubMed ID: 19296110
[TBL] [Abstract][Full Text] [Related]
7. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
Schlenk RF; Döhner K; Krauter J; Fröhling S; Corbacioglu A; Bullinger L; Habdank M; Späth D; Morgan M; Benner A; Schlegelberger B; Heil G; Ganser A; Döhner H;
N Engl J Med; 2008 May; 358(18):1909-18. PubMed ID: 18450602
[TBL] [Abstract][Full Text] [Related]
8. Age-dependent frequencies of NPM1 mutations and FLT3-ITD in patients with normal karyotype AML (NK-AML).
Schneider F; Hoster E; Schneider S; Dufour A; Benthaus T; Kakadia PM; Bohlander SK; Braess J; Heinecke A; Sauerland MC; Berdel WE; Buechner T; Woermann BJ; Feuring-Buske M; Buske C; Creutzig U; Thiede C; Zwaan MC; van den Heuvel-Eibrink MM; Reinhardt D; Hiddemann W; Spiekermann K
Ann Hematol; 2012 Jan; 91(1):9-18. PubMed ID: 21744003
[TBL] [Abstract][Full Text] [Related]
9. Importance of early detection and follow-up of FLT3 mutations in patients with acute myeloid leukemia.
Colovic N; Tosic N; Aveic S; Djuric M; Milic N; Bumbasirevic V; Colovic M; Pavlovic S
Ann Hematol; 2007 Oct; 86(10):741-7. PubMed ID: 17579862
[TBL] [Abstract][Full Text] [Related]
10. Distinctive expression of myelomonocytic markers and down-regulation of CD34 in acute myelogenous leukaemia with FLT3 tandem duplication and nucleophosmin mutation.
Mori Y; Yoshimoto G; Kumano T; Miyamoto T; Iino T; Takenaka K; Iwasaki H; Harada N; Kinukawa N; Nagafuji K; Teshima T; Shimoda K; Akashi K; Harada M
Eur J Haematol; 2007 Jul; 79(1):17-24. PubMed ID: 17598835
[TBL] [Abstract][Full Text] [Related]
11. Cytoplasmic expression of nucleophosmin accurately predicts mutation in the nucleophosmin gene in patients with acute myeloid leukemia and normal karyotype.
Luo J; Qi C; Xu W; Kamel-Reid S; Brandwein J; Chang H
Am J Clin Pathol; 2010 Jan; 133(1):34-40. PubMed ID: 20023256
[TBL] [Abstract][Full Text] [Related]
12. Risk assessment in patients with acute myeloid leukemia and a normal karyotype.
Bienz M; Ludwig M; Leibundgut EO; Mueller BU; Ratschiller D; Solenthaler M; Fey MF; Pabst T
Clin Cancer Res; 2005 Feb; 11(4):1416-24. PubMed ID: 15746041
[TBL] [Abstract][Full Text] [Related]
13. Continuous infusion idarubicin and intravenous busulphan as conditioning regimen to autologous stem cell transplantation for patients with acute myeloid leukaemia.
Ferrara F; Mele G; Palmieri S; Pedata M; Copia C; Riccardi C; Izzo T; Criscuolo C; Musto P
Hematol Oncol; 2009 Dec; 27(4):198-202. PubMed ID: 19475701
[TBL] [Abstract][Full Text] [Related]
14. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study.
Whitman SP; Archer KJ; Feng L; Baldus C; Becknell B; Carlson BD; Carroll AJ; Mrózek K; Vardiman JW; George SL; Kolitz JE; Larson RA; Bloomfield CD; Caligiuri MA
Cancer Res; 2001 Oct; 61(19):7233-9. PubMed ID: 11585760
[TBL] [Abstract][Full Text] [Related]
15. The genotype nucleophosmin mutated and FLT3-ITD negative is characterized by high bax/bcl-2 ratio and favourable outcome in acute myeloid leukaemia.
Del Poeta G; Ammatuna E; Lavorgna S; Capelli G; Zaza S; Luciano F; Ottone T; Del Principe MI; Buccisano F; Maurillo L; Panetta P; de Fabritiis P; Stasi R; Venditti A; Amadori S; Lo Coco F
Br J Haematol; 2010 May; 149(3):383-7. PubMed ID: 20148885
[TBL] [Abstract][Full Text] [Related]
16. FLT3 mutations in normal karyotype acute myeloid leukemia in first complete remission treated with autologous peripheral blood stem cell transplantation.
Yoshimoto G; Nagafuji K; Miyamoto T; Kinukawa N; Takase K; Eto T; Kato K; Hayashi S; Kamimura T; Ohno Y; Taniguchi S; Harada M
Bone Marrow Transplant; 2005 Dec; 36(11):977-83. PubMed ID: 16184177
[TBL] [Abstract][Full Text] [Related]
17. Influence of FLT3-internal tandem duplication allele burden and white blood cell count on the outcome in patients with intermediate-risk karyotype acute myeloid leukemia.
How J; Sykes J; Gupta V; Yee KW; Schimmer AD; Schuh AC; Minden MD; Kamel-Reid S; Brandwein JM
Cancer; 2012 Dec; 118(24):6110-7. PubMed ID: 22736495
[TBL] [Abstract][Full Text] [Related]
18. CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia.
Dang H; Chen Y; Kamel-Reid S; Brandwein J; Chang H
Hum Pathol; 2013 Oct; 44(10):2038-46. PubMed ID: 23701943
[TBL] [Abstract][Full Text] [Related]
19. Role of autologous hematopoietic stem cell transplantation according to the NPM1/FLT3-ITD molecular status for cytogenetically normal AML patients: a GOELAMS study.
Guièze R; Cornillet-Lefebvre P; Lioure B; Blanchet O; Pigneux A; Recher C; Bonmati C; Fegueux N; Bulabois CE; Bouscary D; Vey N; Delain M; Turlure P; Himberlin C; Harousseau JL; Dreyfus F; Béné MC; Ifrah N; Chevallier P;
Am J Hematol; 2012 Dec; 87(12):1052-6. PubMed ID: 22911473
[TBL] [Abstract][Full Text] [Related]
20. Clinical implications of non-A-type NPM1 and FLT3 mutations in patients with normal karyotype acute myeloid leukemia.
Park BG; Chi HS; Park SJ; Min SK; Jang S; Park CJ; Kim DY; Lee JH; Lee JH; Lee KH
Acta Haematol; 2012; 127(2):63-71. PubMed ID: 22104247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
